Amyloid-Beta Protein Made in the Liver May Cause Alzheimer’s Disease in the Brain
Amyloid protein made in the liver can cause neurodegeneration in the brain, according to a new study published on September 14, 2021, in the open-access journal PLOS Biology, by John Mamo of Curtin University in Bentley, Australia, and colleagues. Since the protein is thought to be a key contributor to development of Alzheimer’s disease, the results suggest that the liver may play an important role in the onset or progression of the disease.
Deposits of amyloid-beta protein (A-beta) in the brain are one of the pathological hallmarks of Alzheimer’s disease and are implicated in neurodegeneration in both human patients and animal models of the disease. But amyloid-beta protein is also present in peripheral organs, and blood levels of A-beta correlate with cerebral amyloid burden and cognitive decline, raising the possibility that peripherally produced a-beta may contribute to Alzheimer’s disease. Testing that hypothesis has been difficult, since the brain also produces A-beta, and distinguishing protein from the two sources is challenging.
In the current study, the authors surmounted that challenge by developing a mouse that produces human amyloid-beta protein only in liver cells. They showed that the protein was carried in the blood by triglyceride-rich lipoproteins, just as it is in humans, and passed from the periphery into the brain. They found that mice developed neurodegeneration and brain atrophy, which was accompanied by neurovascular inflammation and dysfunction of cerebral capillaries, both commonly observed with Alzheimer’s disease. Affected mice performed poorly on a learning test that depends on function of the hippocampus, the brain structure that is essential for the formation of new memories.
The findings from this study indicate that peripherally derived amyloid-beta protein has the ability to cause neurodegeneration and suggest that amyloid-beta protein made in the liver is a potential contributor to human disease. If that contribution is significant, the findings may have major implications for understanding Alzheimer’s disease. To date, most models of the disease have focused on brain overproduction of A-beta, which mimics the rare genetic cases of human Alzheimer’s. But for the vast majority of Alzheimer’s disease cases, overproduction of A-beta in the brain is not thought to be central to the disease etiology. Instead, lifestyle factors may play a more important role, including a high-fat diet, which might accelerate liver production of A-beta.
The effects of peripheral A-beta on brain capillaries may be critical in the disease process, Mamo adds. “While further studies are now needed, this finding shows the abundance of these toxic protein deposits in the blood could potentially be addressed through a person’s diet and some drugs that could specifically target lipoprotein amyloid, therefore reducing their risk or slowing the progression of Alzheimer’s disease.”
Alzheimer’s WA Chairman Adjunct Professor Warren Harding said the findings may have a significant global impact for the millions of people living with Alzheimer’s disease.
“Having universities like Curtin working with the pharmaceutical industry is important if we are to tackle this devastating disease,” Mr. Harding said.
“In Australia, approximately 250 people are diagnosed with dementia daily, adding to the staggering half a million Australians who are already living with dementia. Without significant medical advances like the breakthrough Professor Mamo’s team has made, it is estimated that the number of Australians living with dementia will exceed one million by 2058. This has a significant impact on families, carers and communities.”
Professor Mamo and his research team’s previous research in this area was awarded the NHMRC-Marshall and Warren Award for the most innovative and potentially transformative research.
Currently, the team is conducting a clinical trial, the Probucol in Alzheimer’s-clinical trial, which is based on previous findings that a historic cardiovascular agent lowers lipoprotein-amyloid production and supports cognitive performance in mice.